Search Results - "Kremer, J.A."

Pathophysiology of thrombotic thrombocytopenic purpura and hemolytic uremic syndrome by Kremer Hovinga, J. A., Heeb, S. R., Skowronska, M., Schaller, M.

“…Summary Thrombotic microangiopathies are rare disorders characterized by the concomitant occurrence of severe thrombocytopenia, microangiopathic hemolytic…”
Get full text

High prevalence of hereditary thrombotic thrombocytopenic purpura in central Norway: from clinical observation to evidence by Krogh, A. S., Quist‐Paulsen, P., Waage, A., Langseth, Ø. O., Thorstensen, K., Brudevold, R., Tjønnfjord, G. E., Largiadèr, C. R., Lämmle, B., Kremer Hovinga, J. A.

“…Essentials The population prevalence of hereditary thrombotic thrombocytopenic purpura (TTP) is unknown. We studied the prevalence of hereditary TTP and…”
Get full text

Recombinant ADAMTS13 normalizes von Willebrand factor‐cleaving activity in plasma of acquired TTP patients by overriding inhibitory antibodies by PLAIMAUER, B., KREMER HOVINGA, J. A., JUNO, C., WOLFSEGGER, M. J., SKALICKY, S., SCHMIDT, M., GRILLBERGER, L., HASSLACHER, M., KNÖBL, P., EHRLICH, H., SCHEIFLINGER, F.

“…Background: Severe deficiency of the von Willebrand factor (VWF)‐cleaving protease ADAMTS13 as observed in acquired thrombotic thrombocytopenic purpura (TTP)…”
Get full text

ADAMTS‐13, von Willebrand factor and related parameters in severe sepsis and septic shock by KREMER HOVINGA, J. A., ZEERLEDER, S., KESSLER, P., ROMANI DE WIT, T., VAN MOURIK, J. A., HACK, C. E., TEN CATE, H., REITSMA, P. H., WUILLEMIN, W. A., LÄMMLE, B.

“…Background: Insufficient control of von Willebrand factor (VWF) multimer size as a result of severely deficient ADAMTS‐13 activity results in thrombotic…”
Get full text

Second international collaborative study evaluating performance characteristics of methods measuring the von Willebrand factor cleaving protease (ADAMTS‐13) by TRIPODI, A., PEYVANDI, F., CHANTARANGKUL, V., PALLA, R., AFRASIABI, A., CANCIANI, M. T., CHUNG, D. W., FERRARI, S., FUJIMURA, Y., KARIMI, M., KOKAME, K., KREMER HOVINGA, J. A., LÄMMLE, B., DE MEYER, S. F., PLAIMAUER, B., VANHOORELBEKE, K., VARADI, K., MANNUCCI, P. M.

“…Background: Over the last 4 years ADAMTS‐13 measurement underwent dramatic progress with newer and simpler methods. Aims: Blind evaluation of newer methods for…”
Get full text

Morphology studies in type 2 globozoospermia by Dam, A.H, Ramos, L, Westphal, H.R, Dijkman, H, Woestenenk, R.M, Kremer, J.A

Get full text

CLINICAL ASPECTS OF HEREDITARY AND ACQUIRED THROMBOTIC THROMBOCYTOPENIC PURPURA by Hovinga, J.A. Kremer

Get full text

Humoral immune response to ADAMTS13 in acquired thrombotic thrombocytopenic purpura by POS, W., LUKEN, B. M., SORVILLO, N., HOVINGA, J. A. KREMER, VOORBERG, J.

“…The apparently spontaneous development of autoantibodies to ADAMTS13 in previously healthy individuals is a major cause of thrombotic thrombocytopenic purpura…”
Get full text

Plasma DNA is elevated in patients with deep vein thrombosis by Diaz, Jose Antonio, MD, Fuchs, Tobias A., PhD, Jackson, Tatum O., BA, Kremer Hovinga, Johanna A., MD, Lämmle, Bernhard, MD, Henke, Peter K., MD, Myers, Daniel D., DVM, MPH, Wagner, Denisa D., PhD, Wakefield, Thomas W., MD

“…Objective To investigate if plasma DNA is elevated in patients with deep vein thrombosis (DVT) and to determine whether there is a correlation with other…”
Get full text

Von Willebrand factor binds to surface-bound C1q in vitro by Kölm, R., Schaller, M., Vanhecke, D., Hovinga, J.A. Kremer, Khanicheh, E., Kaufmann, B.A., Trendelenburg, M.

Get full text

Caplacizumab reduces the frequency of major thromboembolic events, exacerbations and death in patients with acquired thrombotic thrombocytopenic purpura by Peyvandi, F., Scully, M., Kremer Hovinga, J. A., Knöbl, P., Cataland, S., De Beuf, K., Callewaert, F., De Winter, H., Zeldin, R. K.

“…Essentials Acquired thrombotic thrombocytopenic purpura (aTTP) is linked with significant morbidity/mortality. Caplacizumab's effect on major thromboembolic…”
Get full text

THE DYNAMIC RANGE OF IMMUNOASSAYS FOR HEPARIN-INDUCED THROMBOCYTOPENIA by Nilius, H., Naas, S., Nakas, C., Studt, J., Tsakiris, D.A., Greinacher, A., Mendez, A., Schmidt, A., Wuillemin, W.A., Gerber, B., Kremer Hovinga, J.A., Vishnu, P., Graf, L., Bakchoul, T., Nagler, M.

Get full text

Impaired DNase1‐mediated degradation of neutrophil extracellular traps is associated with acute thrombotic microangiopathies by Jiménez‐Alcázar, M., Napirei, M., Panda, R., Köhler, E. C., Kremer Hovinga, J. A., Mannherz, H. G., Peine, S., Renné, T., Lämmle, B., Fuchs, T. A.

“…Summary Background Acute thrombotic microangiopathies (TMAs) are characterized by excessive microvascular thrombosis and are associated with markers of…”
Get full text

IgG subclass distribution of anti‐ADAMTS13 antibodies in patients with acquired thrombotic thrombocytopenic purpura by FERRARI, S., MUDDE, G. C., RIEGER, M., VEYRADIER, A., KREMER HOVINGA, J. A., SCHEIFLINGER, F.

“…Background: ADAMTS13‐neutralizing IgG autoantibodies are the major cause of acquired thrombotic thrombocytopenic purpura (TTP). Objective: To analyze the IgG…”
Get full text

Establishment of the WHO 1st International Standard ADAMTS13, plasma (12/252): communication from the SSC of the ISTH by Hubbard, A. R., Heath, A. B., Kremer Hovinga, J. A.

Get full text

Thrombotic thrombocytopenic purpura by LÄMMLE, B., KREMER HOVINGA, J. A., ALBERIO, L.

“…This overview summarizes the history of thrombotic thrombocytopenic purpura (TTP) from its initial recognition in 1924 as a most often fatal disease to the…”
Get full text

Measurement of ADAMTS‐13 activity in plasma by the FRETS‐VWF73 assay: comparison with other assay methods by KREMER HOVINGA, J. A., MOTTINI, M., LÄMMLE, B.

Get full text

Hyperbilirubinemia interferes with ADAMTS‐13 activity measurement by FRETS‐VWF73 assay: diagnostic relevance in patients suffering from acute thrombotic microangiopathies by MEYER, S. C., SULZER, I., LÄMMLE, B., KREMER HOVINGA, J. A.

Get full text

Multiple B‐cell clones producing antibodies directed to the spacer and disintegrin/thrombospondin type‐1 repeat 1 (TSP1) of ADAMTS13 in a patient with acquired thrombotic thrombocytopenic purpura by LUKEN, B. M., KAIJEN, P. H. P., TURENHOUT, E. A. M., KREMER HOVINGA, J. A., VAN MOURIK, J. A., FIJNHEER, R., VOORBERG, J.

“…Background: The cysteine‐rich/spacer domains of ADAMTS13 contain a major binding site for antibodies in patients with acquired thrombotic thrombocytopenic…”
Get full text

VH1‐69 germline encoded antibodies directed towards ADAMTS13 in patients with acquired thrombotic thrombocytopenic purpura by POS, W., LUKEN, B. M., KREMER HOVINGA, J. A., TURENHOUT, E. A. M., SCHEIFLINGER, F., DONG, J.‐F., FIJNHEER, R., VOORBERG, J.

“…Background: Autoantibodies directed towards ADAMTS13 are present in the majority of patients with acquired thrombotic thrombocytopenic purpura (TTP). Analysis…”
Get full text